British healthtech start-up Medopad has announced that it is expanding across the Atlantic following a whirlwind success story in the UK.

The company is to set up shop at Johnson & Johnson’s new New York offices after experiencing a 400% year-on-year growth in project value, which has included deals with The Royal Free, Guys and St Thomas’, GSK, Johnson & Johnson and Boston Scientific.

As part of the move, Medopad said it planned to hire “top healthtech talent” as it sets its sights on conquering the US.

The firm said New York presented “an ideal launch pad” into the US market, citing it as “an established nucleus for the life sciences industry”.

Dan Vahdat, CEO of Medopad, said: “We are thrilled to open a base in the USA as part of Johnson & Johnson’s incubator platform JLABS. This is a fantastic opportunity for Medopad as our values and vision are aligned with J&J’s leadership to help create a world where people can live longer.”

Medopad was recently invited to join Pfizer UK’s London accelerator programme after being recognised for its works in patient monitoring and data analytics technologies.

In January this year, the company signed a Memorandum of Understanding (MoU) with Johns Hopkins University to explore new healthcare solutions using machine learning and patient monitoring solutions.

“We have been working in partnership with US pharmaceuticals, healthcare providers and academic institutions such as Johns Hopkins where Medopad is used to connect clinicians to patients remotely and collect real world evidence,” said Vahdat.

“We look forward to strengthening these bonds and driving more innovative change for better health outcomes for people. The remote patient monitoring market is more than eight times bigger in the US vs UK.”